Treatment of Helicobacter pylori in Pediatrics

Springer Science and Business Media LLC - Tập 7 - Trang 407-412 - 2004
Samra S. Blanchard1, Lara Bauman1, Steven J. Czinn1
1Department of Pediatrics, Division of Gastroenterology, Rainbow Babies & Children’s Hospital and Case Western Reserve University, Cleveland, USA

Tóm tắt

Helicobacter pylori (H. pylori) is among the most common bacterial infections in humans. In 1982, H. pylori was discovered by Marshal and Warren, demonstrating an association between H. pylori and ulcer disease. H. pylori is a gram-negative, S-shaped rod that produces enzymes like urease, catalase and oxidase. The mechanism of acquisition and transmission of H. pylori is unclear, although the most likely mode of transmission is fecaloral and oral-oral. The mode of transmission is supported by studies that demonstrate viable H. pylori organisms can be cultured from the stool or vomitus of infected patients. Risk factors such as minimal education and low socio-economic status during childhood affect the prevalence. Children infected with H. pylori develop histologic chronic active gastritis despite the fact that they are generally asymptomatic. A small percentage of these children will go on to develop peptic ulcer disease, and even gastric cancer. In contrast, the association of abdominal pain and H. pylori infection remains controversial. In the year 2000, the North American Society of Pediatric Gastroenterology guidelines on H. pylori reported that there is no evidence demonstrating a link between H. pyloriassociated gastritis and abdominal pain, except in rare cases in which gastric or duodenal ulcer disease is present. Currently, treatment with a combination of two antimicrobial agents in conjunction with a proton pump inhibitor (PPI) continues to be recommended for the treatment of H. pylori associated peptic ulcer disease.

Tài liệu tham khảo

Warren JR, Marshall BJ, et al.: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983, i: 1273–1275.

Marshall BJ, Armstrong JA, McGechie DB, et al.: Attempt to fulfill Koch’s postulate for pyloric Campylobacter. Med J Aust 1985, 142: 436–439.

Morris A, Nicholson G: Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987, 82: 192–199.

Hu L-T, Foxall PA, Russell R, Mobley HL: Purification of recombinant Helicobacter pylori urease apoenzyme encoded by ureA and ureB. Infect Immun 1992, 60: 2657–2666.

Leunk RD, Johnson PT, David BC, et al.: Cytotoxic activity in broth culture filtrates of. Campylobacter pylori. J Med Microbiol 1988, 26: 93–99.

Cover TL, Cao P, Lind CD, et al.: Correlation between vacuolating cytotoxin production by Helicobacter pylori isolates in vitro and in vivo. Infect Immun 1993, 61: 5008–5012.

Crabtree JE, Taylor JD, Wyatt JI, et al.: Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. The Lancet 1991, 338: 332–335.

Tummuru MKR, Cover TL, Blaser MJ, et al.: Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: Evidence of linkage to cytotoxin production. Infection and Immunity 1993, 61: 1799–1809.

Xiang Z, Censini S, Bayeli PF, et al.: Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infection and Immunity 1995, 63: 94–98.

Blaser M: Role of vacA and cagA locus of Helicobacter pylori in human disease. Aliment Pharmacol Ther 1996, 10: 73–77.

Valle J, Kekki M, Sipponen P, et al.: Long-term course and consequences of Helicobacter pylori gastritis. Scand J Gastroenterol 1996, 31: 546–550. Excellent review of the long-term consequences of H. pylori infection.

Malaty HM, Graham DY: Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994, 35: 742–745.

Klein PD, Group Gpw, Graham DY, et al.: Water source as risk factor for Helicobacter pylori infection in Peruvian children. Lancet 1991, 337: 1503–1506.

Forman D, Webb P, Parsonnet J, et al.: H. pylori and gastric cancer. Lancet 1994, 343: 243–244.

Parsonnet J, Friedman GD, Orentreich N, et al.: Risk of gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997, 1997: 297–301.

Hussell T, Isaacson PG, Crabtree JE, et al.: The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993, 342: 571–574.

World Health Organization: Infection with Helicobacter pylori. Schistosomes, Liver Flukes and Helicobacter pylori. Vol. 61. Lyon: International Agency for Research on Cancer, 1994: 177–241.

Cutler AF, Havstad S, Ma CK, et al.: Accuracy of Invasive and Noninvasive Tests to Diagnose Helicobacter pylori Infection. Gastroenterology 1995, 109: 136–141.

Zimmerman A, Walter J, Katona B, et al.: A review of omeprazole us in the treatment of acid-related disorders in children. Clin Ther 2001, 23: 2001.

Tolia V: Helicobacter pylori infection in pediatric patients. Curr Gastroenterol Reports 1999, 1: 308–313.

Gold BD: Current Therapy for Helicobacter pylori infection in Children and adolescents. Can J Gastroenterol 1999, 13: 571–579.

Rowland M, Kumar D, Daly L, et al.: Risk factors for reinfection with Helicobacter pylori. J Pediatr Gastroenterol Nutr 1998, 26: 562.

Kato S, Abukawa D, Furuyama N, et al.: Helicobacter pylori reinfection rates in children after eradication therapy. J Pediatr Gastroenterol Nutr 1998, 27: 543–546.

Michetti P, Kreiss C, Kotloff KL, et al.: Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999, 116: 990–993.

Leung W, Graham D: Rescue therapy for Helicobacter pylori. Curr Treat Options Gastroenterol 2002, 5: 133–138. Practical suggestions for treating patients who fail an initial course of triple therapy.

Malferheiner P, Peitz U: Duodenal Ulcer. Curr Treat Options Gastroenterol 2000, 3: 171–181.

Guslandi M, et al.: Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment Pharmacol Ther 2001, 15: 1543–1547. A good review of antibacterial agents that can be used to treat H. pylori infection.

Walsh D, Goggin N, Rowland M, et al.: One week treatment for Helicobacter pylori infection. Arch Dis child 1997, 76: 352–355.

Driman D, Wright C, Tougas G, et al.: Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Dig Dis Sci 1996, 41: 2039–2047.

Hassall E, Dimmick J, Israel D: Parietal cell hyperplasia in children receiving omeprazole (abstract). Gastroenterology 1995, 108: A110.

Israel D, Hassall E, Dimmick J, et al.: Gastric polyps in children receiving omeprazole (abstract). Gastroenterology 1995, 108: A121.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 7

407-412

Thông tin tác giả